- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about GSK
Recent news which mentions GSK
10 Health Care Stocks With Whale Alerts In Today's Session
April 26, 2023
From Benzinga
3 Biotechs That Might Get Bought Out in 2023
April 26, 2023
From Motley Fool
Was This Acquisition a Savvy Play by This Big Pharma Stock?
April 26, 2023
From Motley Fool
Unlocking Xenon Pharmaceuticals $1B Potential: Analyst Cites Anti-Epileptic Candidate's Untapped Value
April 25, 2023
From Benzinga
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
April 25, 2023
From Motley Fool
Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz
April 24, 2023
From Benzinga
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
April 21, 2023
From Benzinga
Why Shares of Bellus Health Skyrocketed This Week
April 20, 2023
From Motley Fool
Why BELLUS Health Stock Is Rocketing Higher Today
April 18, 2023
From Motley Fool
From Benzinga
Bellus Health’s stock climbs on GSK deal, while Goldman Sachs is hurt by a revenue miss
April 18, 2023
From MarketWatch
Why Is Bellus Health (BLU) Stock Up 98% Today?
April 18, 2023
From InvestorPlace
From MarketWatch
GSK To Strengthen Specialty Medicines and Respiratory Pipeline With $2B BELLUS Health Acquisition
April 18, 2023
From Benzinga
GSK to acquire U.S.-based BELLUS Health for $14.75 per share
April 18, 2023
From MarketWatch
Can Pfizer Beat GSK and Moderna in This $10 Billion Market?
April 13, 2023
From Motley Fool
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
April 11, 2023
From Motley Fool
Biden Administration Launches $5B Program To Boost Development Of Pan-Coronavirus Vaccine, Treatments
April 11, 2023
From Benzinga
2 Top Biotech Stocks to Buy in April
April 04, 2023
From Motley Fool
From Motley Fool
Texas Judge Obstructs Affordable Act Coverage Mandate For Some Cancer Screenings, Prophylaxis
March 31, 2023
From Benzinga
Stage Set For Generics As Biden Admin Asks Supreme Court To Hear Skinny Labels Case Between GSK, Teva
March 31, 2023
From Benzinga
From Benzinga
Why Is Scynexis (SCYX) Stock Up 69% Today?
March 30, 2023
From InvestorPlace
Viatris Among Three Companies Licensed To Make GSK/Pfizer-Backed Long Acting HIV Prevention Drug
March 30, 2023
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.